<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26024444</article-id><article-id pub-id-type="pmc">4449192</article-id><article-id pub-id-type="publisher-id">PONE-D-14-51348</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0126790</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Willingness-To-Accept Pharmaceutical Retail Inconvenience: Evidence from a Contingent Choice Experiment</article-title><alt-title alt-title-type="running-head">Pharmaceutical Retail Inconvenience</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Finlay</surname><given-names>Keith</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Stoecker</surname><given-names>Charles</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Cunningham</surname><given-names>Scott</given-names></name><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="aff001">
<label>1</label>
<addr-line>Department of Economics, Tulane University, New Orleans, LA, USA</addr-line>
</aff><aff id="aff002">
<label>2</label>
<addr-line>Department of Global Health Management and Policy, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA</addr-line>
</aff><aff id="aff003">
<label>3</label>
<addr-line>Department of Economics, Baylor University, Waco, TX, USA</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Bruce</surname><given-names>Amanda</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>The University of Kansas Medical Center, USA</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: KF CS SC. Performed the experiments: KF CS SC. Analyzed the data: KF CS SC. Contributed reagents/materials/analysis tools: KF CS SC. Wrote the paper: KF CS SC.</p></fn><corresp id="cor001">* E-mail: <email>cfstoecker@tulane.edu</email> (CS)</corresp></author-notes><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>29</day><month>5</month><year>2015</year></pub-date><volume>10</volume><issue>5</issue><elocation-id>e0126790</elocation-id><history><date date-type="received"><day>14</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>7</day><month>4</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 Finlay et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Finlay et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0126790.pdf"/><abstract><sec id="sec001"><title>Objectives</title><p>Restrictions on retail purchases of pseudoephedrine are one regulatory approach to reduce the social costs of methamphetamine production and use, but may impose costs on legitimate users of nasal decongestants. This is the first study to evaluate the costs of restricting access to medications on consumer welfare. Our objective was to measure the inconvenience cost consumers place on restrictions for cold medication purchases including identification requirements, purchase limits, over-the-counter availability, prescription requirements, and the active ingredient.</p></sec><sec id="sec002"><title>Methods</title><p>We conducted a contingent choice experiment with Amazon Mechanical Turk workers that presented participants with randomized, hypothetical product prices and combinations of restrictions that reflect the range of public policies. We used a conditional logit model to calculate willingness-to-accept each restriction.</p></sec><sec id="sec003"><title>Results</title><p>Respondents&#x02019; willingness-to-accept prescription requirements was $14.17 ($9.76&#x02013;$18.58) and behind-the-counter restrictions was $9.68 ($7.03&#x02013;$12.33) per box of pseudoephedrine product. Participants were willing to pay $4.09 ($1.66&#x02013;$6.52) per box to purchase pseudoephedrine-based products over phenylephrine-based products.</p></sec><sec id="sec004"><title>Conclusions</title><p>Restricting access to medicines as a means of reducing the social costs of non-medical use can imply large inconvenience costs for legitimate consumers. These results are relevant to discussions of retail access restrictions on other medications.</p></sec></abstract><funding-group><funding-statement>This work was supported by the National Science Foundation award SMA-1004569 (<ext-link ext-link-type="uri" xlink:href="http://www.nsf.gov">www.nsf.gov</ext-link>, KF SC) and the Robert Wood Johnson Foundation (Public Health Law Research award 70509, <ext-link ext-link-type="uri" xlink:href="http://publichealthlawresearch.org/">http://publichealthlawresearch.org/</ext-link>, KF SC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="3"/><page-count count="10"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files. The dataset can be read with Stata software version 13 or higher.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files. The dataset can be read with Stata software version 13 or higher.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>Methamphetamine (meth) use is a significant social ill that has been linked to personal consequences ranging from dropping out of school [<xref rid="pone.0126790.ref001" ref-type="bibr">1</xref>] to heart attacks [<xref rid="pone.0126790.ref002" ref-type="bibr">2</xref>], and social consequences from violent behavior [<xref rid="pone.0126790.ref003" ref-type="bibr">3</xref>] to increased infectious disease transmission [<xref rid="pone.0126790.ref004" ref-type="bibr">4</xref>]. Methamphetamine can be easily synthesized in small batches from precursor ingredients found in widely available nasal decongestant medicines containing pseudoephedrine (pseudo) [<xref rid="pone.0126790.ref005" ref-type="bibr">5</xref>]. Due to these social costs, policies have been enacted since the early 1990s to curtail domestic access to pseudo in an effort to reduce domestic meth synthesis and, ultimately, consumption via the policy&#x02019;s effect on meth availability and prices.</p><p>Increased sales of pseudo have been linked with increased meth production [<xref rid="pone.0126790.ref006" ref-type="bibr">6</xref>], so regulations have placed legal constraints on retail sales at pharmacies. Retail pharmacy regulations that restrict consumer purchase of pseudo are usually bundled constraints along numerous dimensions. For instance, the federal Combat Methamphetamine Epidemic Act of 2005 restricted retail purchases to no more than 9 grams of pseudo per month, required consumers to present proof of identification at point of purchase, and moved pseudo behind the counter. Oregon and Mississippi enacted &#x0201c;prescription-only&#x0201d; laws in 2006 and 2010, respectively, that further restricted access. At least a dozen states have passed laws that require pharmacies to record all identifying information from consumer purchases of pseudo into a centralized database for real-time tracking.</p><p>Each of these constraints impacts legal consumers of pseudo by raising the marginal cost of purchase. Requiring identification may impose direct costs, and potentially cause equity issues, since obtaining official identification may be more burdensome to lower-income consumers [<xref rid="pone.0126790.ref007" ref-type="bibr">7</xref>]. Purchase limits may impose inconvenience costs such as additional time or costs for travel. Prescription requirements include direct costs, travel costs, time costs to both patient and prescribing doctor, and can be substantial [<xref rid="pone.0126790.ref008" ref-type="bibr">8</xref>]. A full evaluation of these interventions would compare the benefits of each of these strategies, including potentially reduced social costs of methamphetamine production and use, with the harms.</p><p>Previous work has speculated about the existence of substantial costs of access restrictions to medications in general to consumer welfare [<xref rid="pone.0126790.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0126790.ref010" ref-type="bibr">10</xref>]. Studies have explored the consequences of interactions of prescription requirements and insurance status on consumer costs [<xref rid="pone.0126790.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0126790.ref012" ref-type="bibr">12</xref>]. This is the first study, however, to measure the inconvenience burden to consumers associated with medication access restrictions.</p><p>In this paper, we aim to identify the costs to consumers of identification requirements, purchase limits, behind-the-counter requirements, or prescription requirements. We use a contingent choice experiment and model responses with a conditional logit to calculate willingness-to-accept each restriction.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Methods</title><sec id="sec007"><title>0.1 The choice experiment</title><p>We asked 2,000 survey participants to suppose they were interested in buying cold medicine. After a brief orientation to the two principal active ingredients in nasal decongestants (included in <xref rid="pone.0126790.s001" ref-type="supplementary-material">S1 Pseudo Orientation</xref>), each participant was asked to choose an option for treating a cold. Respondents were presented with a set of 4 choices: 2 pseudo-based product options with different restrictions, a phenylephrine-based (phenyl) product with no restrictions, or a no-purchase option. We included the phenyl alternative to pseudo to capture some measure of how willing consumers would be to substitute away from pseudo medications to possibly less effective and less restricted phenyl medications. Each participant was presented with 10 randomly ordered sets of 4 randomly ordered alternatives. We chose 4 alternatives as this is close to an optimal choice set size [<xref rid="pone.0126790.ref015" ref-type="bibr">15</xref>]. The Tulane University IRB Board determined this study was exempt from oversight.</p><p>Phenyl decongestants (such as Sudafed Pressure and Pain) are widely available in retail pharmacies and marketed as an effective over-the-counter alternative to pseudo-based nasal decongestants (such as Sudafed 12-Hour). On a molecular level, these chemicals differ in how much is metabolized by the body and which receptors are affected. Only 38% of phenyl is absorbed for effective use by the body compared with 100% for pseudo. Pseudo is a stimulant that releases adrenaline, whereas phenyl does not have this effect. Whereas the efficacy of pseudo as a nasal decongestant is supported by numerous controlled trials, there is little evidence that oral phenyl performs better than placebo [<xref rid="pone.0126790.ref013" ref-type="bibr">13</xref>]. See Eccles [<xref rid="pone.0126790.ref014" ref-type="bibr">14</xref>] for a detailed comparison between pseudo- and phenyl-based nasal decongestants.</p><p>The pseudo options were presented with restrictions including an identification requirement at the point of purchase, a purchase limit, a prescription requirement, or availability restricted to behind-the-counter. In order to reduce the number of options presented, we used a D-efficiency criterion to construct our alternatives. For each alternative there were 5 attributes: active ingredient (psuedo, phenyl, or no purchase), price (random, random with a discount), ID requirement (yes, no), purchase limit (yes, no), and purchase experience (easy to buy as Tylenol, behind the counter, prescription). This left us with 72 possible alternatives. In order to administer the choice experiment that minimized the variance of estimators we selected the set of alternatives that maximized D-efficiency by choosing the set with that maximizesd the determinant of the information matrix [<xref rid="pone.0126790.ref016" ref-type="bibr">16</xref>]. We eliminated illogical combinations of restrictions (such as prescription requirements that do not also include an ID requirement) and dominated alternatives, as suggested by [<xref rid="pone.0126790.ref017" ref-type="bibr">17</xref>] and [<xref rid="pone.0126790.ref018" ref-type="bibr">18</xref>], (such as phenyl with purchase restrictions). This procedure left 11 potential alternatives. The 7 salient alternatives shown in <xref ref-type="table" rid="pone.0126790.t001">Table 1</xref> maximized the determinant of the information matrix. The alternatives we presented to respondents were 1) pseudo requiring identification and prescription, 2) pseudo requiring identification and with a 1 box per month limit, 3) pseudo with a 1 box per month limit, 4) pseudo requiring identification, 5) pseudo without restrictions, 6) phenyl without restrictions, and 7) no purchase.</p><table-wrap id="pone.0126790.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0126790.t001</object-id><label>Table 1</label><caption><title>Contingent choice alternatives.</title></caption><alternatives><graphic id="pone.0126790.t001g" xlink:href="pone.0126790.t001"/><table frame="box" rules="all" border="0"><colgroup span="1"><col align="left" valign="top" span="1"/><col align="left" valign="top" span="1"/><col align="left" valign="top" span="1"/><col align="left" valign="top" span="1"/><col align="left" valign="top" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Alt. (1)</th><th align="left" rowspan="1" colspan="1">Active ingredient (2)</th><th align="left" rowspan="1" colspan="1">ID required (3)</th><th align="left" rowspan="1" colspan="1">Purchase limit (4)</th><th align="left" rowspan="1" colspan="1">Purchase experience (5)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Pseudo.</td><td align="left" rowspan="1" colspan="1">&#x000d7;</td><td align="left" rowspan="1" colspan="1">set by doctor</td><td align="left" rowspan="1" colspan="1">R<sub>x</sub>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Pseudo.</td><td align="left" rowspan="1" colspan="1">&#x000d7;</td><td align="left" rowspan="1" colspan="1">1 box/month</td><td align="left" rowspan="1" colspan="1">BTC</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Pseudo.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1 box/month</td><td align="left" rowspan="1" colspan="1">BTC</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Pseudo.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">no limit</td><td align="left" rowspan="1" colspan="1">OTC</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Pseudo.</td><td align="left" rowspan="1" colspan="1">&#x000d7;</td><td align="left" rowspan="1" colspan="1">no limit</td><td align="left" rowspan="1" colspan="1">BTC</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Phenyl.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">no limit</td><td align="left" rowspan="1" colspan="1">OTC</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">[No purchase]</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Notes: Each choice set consisted of a pair of pseudoephedrine alternatives along with the phenylephrine and no-buy alternatives.</p></fn></table-wrap-foot></table-wrap><p>Each of the purchased options was presented with an out-of-pocket price, which we modeled as a draw from a base price distribution and accompanying discount factor. The base prices were drawn from a uniform distribution between $6 and $30 independently for each option. To account for the compensating differentials buyers would require for potential restrictions, we further applied a discount to pseudo. The discount was drawn from a uniform distribution that was between $1 and $1 less than the base price. For example, a pseudo option with a randomized base price of $13 could have a discount of $4. When users were presented with a pseudo purchase option without restriction we added a number between $1 and $1 less than the base price to the pseudo option to account for compensation buyers would require when purchasing the option with the potentially less desirable active ingredient. The respondent was only presented with the final price, in this case $9. <xref ref-type="fig" rid="pone.0126790.g001">Fig 1</xref> shows an example choice screen used in the experiment. At the start of the survey we asked respondents what their out-of-pocket expense was when they went to the doctor&#x02019;s office, for use in later analysis.</p><fig id="pone.0126790.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0126790.g001</object-id><label>Fig 1</label><caption><p>Example choice set screen from contingent choice survey.</p></caption><graphic xlink:href="pone.0126790.g001"/></fig><p>We used this Choice Experiment (CE) method instead of directly asking participants to report monetary values for each restriction. Direct question surveys can lead to respondents valuing whole items instead of the attributes of the choices [<xref rid="pone.0126790.ref019" ref-type="bibr">19</xref>]. The CE method allows us to calculate a value for each specific attribute. It is also efficient at drawing information from respondents by allowing us to elicit values for several potential permutations of precursor restrictions in each test. For a thorough review of the CE method in health applications, see [<xref rid="pone.0126790.ref020" ref-type="bibr">20</xref>], and for detailed descriptions of choice experiment design see, [<xref rid="pone.0126790.ref021" ref-type="bibr">21</xref>] and [<xref rid="pone.0126790.ref022" ref-type="bibr">22</xref>].</p></sec><sec id="sec008"><title>0.2 Mechanical Turk</title><p>We administered our survey online using Amazon Mechanical Turk in November 2014. Mechanical Turk provides an online marketplace that connects occasional Internet workers (here survey respondents) with labor purchasers. We paid each respondent $1, which is slightly higher than the typical compensation [<xref rid="pone.0126790.ref023" ref-type="bibr">23</xref>]. Results from field and laboratory surveys and experiments have been replicated using Mechanical Turk [<xref rid="pone.0126790.ref024" ref-type="bibr">24</xref>]. Survey responses from Mechanical Turk are typically more representative than from other online survey mechanisms or convenience samples of college students [<xref rid="pone.0126790.ref025" ref-type="bibr">25</xref>]. We further refined the representativeness of our analysis by calculating survey weights for our respondents [<xref rid="pone.0126790.ref026" ref-type="bibr">26</xref>] to replicate the characteristics of the general population from the 2012 5-year American Community Survey (ACS). The ACS is administered annual by the U.S. Census Bureau to 3 million households. The ACS 5-year release contains the most recent 5-years of data. We balanced respondents in our sample with those in the ACS according to gender, race, highest education completed, number in the household, marital status, census division, and household income. The standardized differences in these attributes between our sample and the ACS are shown in <xref ref-type="table" rid="pone.0126790.t002">Table 2</xref>. After weighting, the standardized difference between our survey respondents and the population average from the ACS was less than 0.00001 for each category of observable characteristics.</p><table-wrap id="pone.0126790.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0126790.t002</object-id><label>Table 2</label><caption><title>Means and standard errors of weighting variables, ACS reference sample, unweighted MTurk sample, weighted MTurk sample.</title></caption><alternatives><graphic id="pone.0126790.t002g" xlink:href="pone.0126790.t002"/><table frame="box" rules="all" border="0"><colgroup span="1"><col align="left" valign="top" span="1"/><col align="left" valign="top" span="1"/><col align="left" valign="top" span="1"/><col align="left" valign="top" span="1"/><col align="left" valign="top" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">ACS sample (1)</th><th align="left" rowspan="1" colspan="1">Unweighted MTurk sample (2)</th><th align="left" rowspan="1" colspan="1">Weighted MTurk sample (3)</th><th align="left" rowspan="1" colspan="1">Standardized diff.: (3)&#x02212;(1) (4)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="char" char="." rowspan="1" colspan="1">0.519</td><td align="char" char="." rowspan="1" colspan="1">0.458</td><td align="char" char="." rowspan="1" colspan="1">0.519</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Asian</td><td align="char" char="." rowspan="1" colspan="1">0.057</td><td align="char" char="." rowspan="1" colspan="1">0.090</td><td align="char" char="." rowspan="1" colspan="1">0.057</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Black</td><td align="char" char="." rowspan="1" colspan="1">0.122</td><td align="char" char="." rowspan="1" colspan="1">0.088</td><td align="char" char="." rowspan="1" colspan="1">0.122</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">White</td><td align="char" char="." rowspan="1" colspan="1">0.779</td><td align="char" char="." rowspan="1" colspan="1">0.830</td><td align="char" char="." rowspan="1" colspan="1">0.779</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Hispanic</td><td align="char" char="." rowspan="1" colspan="1">0.143</td><td align="char" char="." rowspan="1" colspan="1">0.100</td><td align="char" char="." rowspan="1" colspan="1">0.143</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household size: 1</td><td align="char" char="." rowspan="1" colspan="1">0.139</td><td align="char" char="." rowspan="1" colspan="1">0.200</td><td align="char" char="." rowspan="1" colspan="1">0.139</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household size: 2</td><td align="char" char="." rowspan="1" colspan="1">0.336</td><td align="char" char="." rowspan="1" colspan="1">0.303</td><td align="char" char="." rowspan="1" colspan="1">0.336</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household size: 3</td><td align="char" char="." rowspan="1" colspan="1">0.194</td><td align="char" char="." rowspan="1" colspan="1">0.229</td><td align="char" char="." rowspan="1" colspan="1">0.194</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household size: 4</td><td align="char" char="." rowspan="1" colspan="1">0.171</td><td align="char" char="." rowspan="1" colspan="1">0.160</td><td align="char" char="." rowspan="1" colspan="1">0.171</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household size: 5</td><td align="char" char="." rowspan="1" colspan="1">0.088</td><td align="char" char="." rowspan="1" colspan="1">0.070</td><td align="char" char="." rowspan="1" colspan="1">0.088</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household size: 6+</td><td align="char" char="." rowspan="1" colspan="1">0.072</td><td align="char" char="." rowspan="1" colspan="1">0.037</td><td align="char" char="." rowspan="1" colspan="1">0.072</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Up to high school graduate</td><td align="char" char="." rowspan="1" colspan="1">0.427</td><td align="char" char="." rowspan="1" colspan="1">0.112</td><td align="char" char="." rowspan="1" colspan="1">0.427</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Some college</td><td align="char" char="." rowspan="1" colspan="1">0.233</td><td align="char" char="." rowspan="1" colspan="1">0.281</td><td align="char" char="." rowspan="1" colspan="1">0.233</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">2-year college degree</td><td align="char" char="." rowspan="1" colspan="1">0.074</td><td align="char" char="." rowspan="1" colspan="1">0.121</td><td align="char" char="." rowspan="1" colspan="1">0.074</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">4-year college degree</td><td align="char" char="." rowspan="1" colspan="1">0.171</td><td align="char" char="." rowspan="1" colspan="1">0.367</td><td align="char" char="." rowspan="1" colspan="1">0.171</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Masters degree</td><td align="char" char="." rowspan="1" colspan="1">0.084</td><td align="char" char="." rowspan="1" colspan="1">0.113</td><td align="char" char="." rowspan="1" colspan="1">0.084</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Doctorate degree</td><td align="char" char="." rowspan="1" colspan="1">0.011</td><td align="char" char="." rowspan="1" colspan="1">0.007</td><td align="char" char="." rowspan="1" colspan="1">0.011</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Never married/single</td><td align="char" char="." rowspan="1" colspan="1">0.269</td><td align="char" char="." rowspan="1" colspan="1">0.547</td><td align="char" char="." rowspan="1" colspan="1">0.269</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Married</td><td align="char" char="." rowspan="1" colspan="1">0.533</td><td align="char" char="." rowspan="1" colspan="1">0.359</td><td align="char" char="." rowspan="1" colspan="1">0.533</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Separated</td><td align="char" char="." rowspan="1" colspan="1">0.023</td><td align="char" char="." rowspan="1" colspan="1">0.015</td><td align="char" char="." rowspan="1" colspan="1">0.023</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Divorced</td><td align="char" char="." rowspan="1" colspan="1">0.114</td><td align="char" char="." rowspan="1" colspan="1">0.067</td><td align="char" char="." rowspan="1" colspan="1">0.114</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Widowed</td><td align="char" char="." rowspan="1" colspan="1">0.061</td><td align="char" char="." rowspan="1" colspan="1">0.012</td><td align="char" char="." rowspan="1" colspan="1">0.061</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">New England</td><td align="char" char="." rowspan="1" colspan="1">0.048</td><td align="char" char="." rowspan="1" colspan="1">0.047</td><td align="char" char="." rowspan="1" colspan="1">0.048</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Middle Atlantic</td><td align="char" char="." rowspan="1" colspan="1">0.134</td><td align="char" char="." rowspan="1" colspan="1">0.132</td><td align="char" char="." rowspan="1" colspan="1">0.134</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">East North Central</td><td align="char" char="." rowspan="1" colspan="1">0.150</td><td align="char" char="." rowspan="1" colspan="1">0.151</td><td align="char" char="." rowspan="1" colspan="1">0.150</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">West North Central</td><td align="char" char="." rowspan="1" colspan="1">0.066</td><td align="char" char="." rowspan="1" colspan="1">0.058</td><td align="char" char="." rowspan="1" colspan="1">0.066</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">South Atlantic</td><td align="char" char="." rowspan="1" colspan="1">0.196</td><td align="char" char="." rowspan="1" colspan="1">0.239</td><td align="char" char="." rowspan="1" colspan="1">0.196</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">East South Central</td><td align="char" char="." rowspan="1" colspan="1">0.060</td><td align="char" char="." rowspan="1" colspan="1">0.063</td><td align="char" char="." rowspan="1" colspan="1">0.060</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">West South Central</td><td align="char" char="." rowspan="1" colspan="1">0.114</td><td align="char" char="." rowspan="1" colspan="1">0.085</td><td align="char" char="." rowspan="1" colspan="1">0.114</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Mountain</td><td align="char" char="." rowspan="1" colspan="1">0.070</td><td align="char" char="." rowspan="1" colspan="1">0.066</td><td align="char" char="." rowspan="1" colspan="1">0.070</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Pacific</td><td align="char" char="." rowspan="1" colspan="1">0.161</td><td align="char" char="." rowspan="1" colspan="1">0.159</td><td align="char" char="." rowspan="1" colspan="1">0.161</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household income under $20K</td><td align="char" char="." rowspan="1" colspan="1">0.134</td><td align="char" char="." rowspan="1" colspan="1">0.148</td><td align="char" char="." rowspan="1" colspan="1">0.134</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household income $20&#x02013;30K</td><td align="char" char="." rowspan="1" colspan="1">0.093</td><td align="char" char="." rowspan="1" colspan="1">0.137</td><td align="char" char="." rowspan="1" colspan="1">0.093</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household income $30&#x02013;40K</td><td align="char" char="." rowspan="1" colspan="1">0.094</td><td align="char" char="." rowspan="1" colspan="1">0.133</td><td align="char" char="." rowspan="1" colspan="1">0.094</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household income $40&#x02013;50K</td><td align="char" char="." rowspan="1" colspan="1">0.090</td><td align="char" char="." rowspan="1" colspan="1">0.121</td><td align="char" char="." rowspan="1" colspan="1">0.090</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household income $50&#x02013;60K</td><td align="char" char="." rowspan="1" colspan="1">0.084</td><td align="char" char="." rowspan="1" colspan="1">0.104</td><td align="char" char="." rowspan="1" colspan="1">0.084</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household income $60&#x02013;70K</td><td align="char" char="." rowspan="1" colspan="1">0.076</td><td align="char" char="." rowspan="1" colspan="1">0.080</td><td align="char" char="." rowspan="1" colspan="1">0.076</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household income $70&#x02013;80K</td><td align="char" char="." rowspan="1" colspan="1">0.067</td><td align="char" char="." rowspan="1" colspan="1">0.073</td><td align="char" char="." rowspan="1" colspan="1">0.067</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household income $80&#x02013;90K</td><td align="char" char="." rowspan="1" colspan="1">0.058</td><td align="char" char="." rowspan="1" colspan="1">0.049</td><td align="char" char="." rowspan="1" colspan="1">0.058</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household income $90&#x02013;100K</td><td align="char" char="." rowspan="1" colspan="1">0.048</td><td align="char" char="." rowspan="1" colspan="1">0.047</td><td align="char" char="." rowspan="1" colspan="1">0.048</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household income $100&#x02013;110K</td><td align="char" char="." rowspan="1" colspan="1">0.043</td><td align="char" char="." rowspan="1" colspan="1">0.039</td><td align="char" char="." rowspan="1" colspan="1">0.043</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household income $110&#x02013;120K</td><td align="char" char="." rowspan="1" colspan="1">0.034</td><td align="char" char="." rowspan="1" colspan="1">0.012</td><td align="char" char="." rowspan="1" colspan="1">0.034</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household income $120&#x02013;130K</td><td align="char" char="." rowspan="1" colspan="1">0.029</td><td align="char" char="." rowspan="1" colspan="1">0.016</td><td align="char" char="." rowspan="1" colspan="1">0.029</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household income $130&#x02013;140K</td><td align="char" char="." rowspan="1" colspan="1">0.023</td><td align="char" char="." rowspan="1" colspan="1">0.007</td><td align="char" char="." rowspan="1" colspan="1">0.023</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household income $140&#x02013;150K</td><td align="char" char="." rowspan="1" colspan="1">0.019</td><td align="char" char="." rowspan="1" colspan="1">0.007</td><td align="char" char="." rowspan="1" colspan="1">0.019</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.00000</td></tr><tr><td align="left" rowspan="1" colspan="1">Household income over $150K</td><td align="char" char="." rowspan="1" colspan="1">0.109</td><td align="char" char="." rowspan="1" colspan="1">0.028</td><td align="char" char="." rowspan="1" colspan="1">0.109</td><td align="char" char="." rowspan="1" colspan="1">0.00000</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Notes: The ACS reference sample includes all individuals aged at least 18 years and not living in institutions.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec009"><title>0.3 Conditional logit</title><p>We used the conditional logit to model consumer responses to product attributes for cold medication. The conditional logit model can estimate how the attributes of a choice influence the probability of being chosen from among several alternatives. Specifically we modeled the probability of choice <italic>j</italic> out of <italic>J</italic> total choices as:
<disp-formula id="pone.0126790.e001"><alternatives><graphic xlink:href="pone.0126790.e001.jpg" id="pone.0126790.e001g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M1"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi mathvariant="normal">Pr</mml:mi><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mi>P</mml:mi></mml:msub><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>J</mml:mi></mml:munderover><mml:mrow><mml:mi>exp</mml:mi></mml:mrow></mml:mstyle><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mi>P</mml:mi></mml:msub><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></alternatives><label>(1)</label></disp-formula>
where <italic>p</italic>
<sub><italic>ij</italic></sub> was the probability individual <italic>i</italic> makes choice <italic>j</italic>. Each choice was defined by a price given by <italic>P</italic>
<sub><italic>ij</italic></sub> and a set of restriction indicators each represented by <italic>R</italic>
<sub><italic>ijn</italic></sub>. The impact of price on the probability of choice was captured by the <italic>&#x003b2;</italic>
<sub><italic>P</italic></sub> parameter and the impact of the <italic>n</italic>
<sup>th</sup> restriction on choice was captured by the parameter <italic>&#x003b2;</italic>
<sub><italic>R</italic><sub><italic>n</italic></sub></sub>. For choices involving prescription-only restrictions we included the self-reported copay amounts as part of the price when modeling the impact of price on choice in the conditional logit models. We recovered the willingness-to-accept a particular restriction from the ratio of the estimated restriction parameter to the price parameter, namely <inline-formula id="pone.0126790.e002"><mml:math id="M2"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mrow><mml:mi>W</mml:mi><mml:mi>T</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover><mml:msub><mml:mi>R</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:msub><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>&#x003b2;</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mrow><mml:mi>R</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>&#x003b2;</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>P</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>. Standard errors for the willingness-to-accept estimates were calculated with the delta method [<xref rid="pone.0126790.ref027" ref-type="bibr">27</xref>]. We used robust standard errors that accounted for within-respondent error correlation. To simplify the choice modeling, we disregard choices that result in non-purchase. In order to test for potential heterogeneity in demand for decongestants between those with and without experience with the medicine, we estimated an alternative specification that restricted the population to respondents who had purchased pseudo decongestants in the last year.</p></sec></sec><sec sec-type="results" id="sec010"><title>Results</title><p>
<xref ref-type="table" rid="pone.0126790.t003">Table 3</xref> shows the results from the conditional logit model. Column 1 gives the impact of each product attribute (price or restriction) on the probability of choice. Column 2 displays willingness-to-accept each restriction. Negative values in Column 2 correspond to desirable product attributes that respondents would pay more for. The amount respondents would require to be willing to accept an undesirable product attribute is denoted with a positive value. We found respondents were willing to accept behind-the-counter restrictions in exchange for $9.68 on average. The willingness-to-accept a more burdensome prescription requirement was $14.17. Participants were willing-to-accept a substitute phenyl-based medication instead of a pseudo-based one for $4.09, which was less than the value participants placed on the behind-the-counter and prescription restrictions. Requiring identification did not significantly impact respondent purchase decisions, the coefficient was small in magnitude and statistically insignificant at the 5% level. Respondents valued imposing purchase limits as a positive attribute for which they were willing to accept price increases, though this counter-intuitive estimate was smaller in magnitude than the undesirable restrictions.</p><table-wrap id="pone.0126790.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0126790.t003</object-id><label>Table 3</label><caption><title>Conditional logit models of cold medicine choice, baseline model and with demand interactions, with sampling weights.</title></caption><alternatives><graphic id="pone.0126790.t003g" xlink:href="pone.0126790.t003"/><table frame="box" rules="all" border="0"><colgroup span="1"><col align="left" valign="top" span="1"/><col align="left" valign="top" span="1"/><col align="left" valign="top" span="1"/><col align="left" valign="top" span="1"/><col align="left" valign="top" span="1"/></colgroup><thead><tr><th rowspan="3" align="left" colspan="1">
<italic>Attributes</italic>
</th><th colspan="2" align="center" rowspan="1">All respondents</th><th colspan="2" align="center" rowspan="1">Past pseudo. purchase</th></tr><tr><th align="left" rowspan="1" colspan="1">(1)</th><th align="left" rowspan="1" colspan="1">(2)</th><th align="left" rowspan="1" colspan="1">(3)</th><th align="left" rowspan="1" colspan="1">(4)</th></tr><tr><th align="left" rowspan="1" colspan="1">Coefficients</th><th align="left" rowspan="1" colspan="1">WTA</th><th align="left" rowspan="1" colspan="1">Coefficients</th><th align="left" rowspan="1" colspan="1">WTA</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total price (dollars)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.10<xref rid="t003fn003" ref-type="table-fn">***</xref> (0.01)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02212;0.10<xref rid="t003fn003" ref-type="table-fn">***</xref> (0.02)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Purchase experience</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Over-the-counter (reference)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Behind-the-counter but no prescription</td><td align="left" rowspan="1" colspan="1">0.98<xref rid="t003fn003" ref-type="table-fn">***</xref> (0.12)</td><td align="left" rowspan="1" colspan="1">9.68<xref rid="t003fn003" ref-type="table-fn">***</xref> (1.35)</td><td align="left" rowspan="1" colspan="1">1.20<xref rid="t003fn003" ref-type="table-fn">***</xref> (0.20)</td><td align="left" rowspan="1" colspan="1">12.43<xref rid="t003fn003" ref-type="table-fn">***</xref> (2.38)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Require doctor&#x02019;s prescription</td><td align="left" rowspan="1" colspan="1">1.44<xref rid="t003fn003" ref-type="table-fn">***</xref> (0.24)</td><td align="left" rowspan="1" colspan="1">14.17<xref rid="t003fn003" ref-type="table-fn">***</xref> (2.25)</td><td align="left" rowspan="1" colspan="1">1.48<xref rid="t003fn003" ref-type="table-fn">***</xref> (0.37)</td><td align="left" rowspan="1" colspan="1">15.38<xref rid="t003fn003" ref-type="table-fn">***</xref> (3.56)</td></tr><tr><td align="left" rowspan="1" colspan="1">Active ingredient</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Pseudoephedrine (reference)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Phenylephrine</td><td align="left" rowspan="1" colspan="1">0.42<xref rid="t003fn003" ref-type="table-fn">***</xref> (0.12)</td><td align="left" rowspan="1" colspan="1">4.09<xref rid="t003fn003" ref-type="table-fn">***</xref> (1.24)</td><td align="left" rowspan="1" colspan="1">0.71<xref rid="t003fn003" ref-type="table-fn">***</xref> (0.22)</td><td align="left" rowspan="1" colspan="1">7.35<xref rid="t003fn003" ref-type="table-fn">***</xref> (2.26)</td></tr><tr><td align="left" rowspan="1" colspan="1">ID requirement</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No ID required (reference)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;ID required</td><td align="left" rowspan="1" colspan="1">&#x02212;0.07 (0.09)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.65 (0.88)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.24<xref rid="t003fn002" ref-type="table-fn">**</xref> (0.11)</td><td align="left" rowspan="1" colspan="1">&#x02212;2.54<xref rid="t003fn002" ref-type="table-fn">**</xref> (1.14)</td></tr><tr><td align="left" rowspan="1" colspan="1">Purchase limit</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No limit (reference)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Any limit</td><td align="left" rowspan="1" colspan="1">&#x02212;0.39<xref rid="t003fn003" ref-type="table-fn">***</xref> (0.08)</td><td align="left" rowspan="1" colspan="1">&#x02212;3.85<xref rid="t003fn003" ref-type="table-fn">***</xref> (0.76)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.49<xref rid="t003fn003" ref-type="table-fn">***</xref> (0.12)</td><td align="left" rowspan="1" colspan="1">&#x02212;5.08<xref rid="t003fn003" ref-type="table-fn">***</xref> (1.16)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;
<italic>Specification</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Pseudo R<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">0.24</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.22</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">N (respondents)</td><td align="left" rowspan="1" colspan="1">1,561</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">648</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">N (choice sets)</td><td align="left" rowspan="1" colspan="1">12,603</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">5,168</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">N (alternatives)</td><td align="left" rowspan="1" colspan="1">37,809</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">15,504</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>Notes: Standard errors that account for arbitrary correlation of errors by respondent in parentheses. Standard errors for willingness-to-accept (WTA) estimates are calculated with the delta method. Stars indicate statistical significance:</p></fn><fn id="t003fn002"><p>**<italic>p</italic> &#x0003c; 0.01.</p></fn><fn id="t003fn003"><p>***<italic>p</italic> &#x0003c; 0.001.</p></fn></table-wrap-foot></table-wrap><p>The model in Columns 3 and 4 is restricted to respondents with recent experience with pseudo. Experienced pseudo purchasers comprised approximately 60% of our sample and placed slightly higher valuations on sales restrictions than the inexperienced survey respondents. Experienced pseudo users valued an active ingredient of phenyl over pseudo at $7.35 which was significantly higher than the $4.09 for the full sample.</p></sec><sec sec-type="conclusions" id="sec011"><title>Discussion</title><p>We administered a choice experiment to assess willingness-to-accept inconvenience when purchasing pseudo-based nasal decongestants. We found respondents required $9.68 to accept behind-the-counter purchases, and $14.17 to accept prescription requirements. We also found consumers were willing to pay $4.09 for pseudo-based products compared to phenyl-based products.</p><p>Retail-level regulations requiring prescriptions for purchase or medication to be stored behind-the-counter may make it more difficult for illegal small-batch meth producers to obtain sufficient amounts of precursor needed to produce meth. But the regulations cannot discriminate between a consumer acquiring pseudo to treat cold symptoms and a consumer acquiring pseudo to manufacture meth, so the burden falls on both legitimate and illegitimate consumers.</p><p>There are several important limitations to our study. First, our choice experiment presented respondents with theoretical scenarios with different prices and restrictions. Previous studies have found that respondents do not necessarily pick the option with the maximum payoff [<xref rid="pone.0126790.ref028" ref-type="bibr">28</xref>]. Respondents in our study may be picking options without proper attention to price variables in our study. If respondents placed more weight on the prescription or other requirements in our experiment than they would have outside of the experimental setting, we would overestimate the willingness-to-accept these requirements.</p><p>Second, while both simple and complex experimental results from surveys conducted with Amazon Mechanical Turk have been cross-validated with results from populations derived in other settings [<xref rid="pone.0126790.ref024" ref-type="bibr">24</xref>, <xref rid="pone.0126790.ref029" ref-type="bibr">29</xref>], some differences between Mechanical Turk workers and the general popultion have been identified. Amazon Mechanical Turk workers are generally less susceptible to subtly induced biases in survey questionnaire wording or misleading questions than are other reference populations [<xref rid="pone.0126790.ref030" ref-type="bibr">30</xref>]. Our survey was kept simple to mitigate such concerns when extrapolating our results to the general population.</p><p>We estimated weights to match the demographics of our survey respondents to those of the United States population. It is possible, however, that respondents may differ in unobservable characteristics. All Mechanical Turk workers have access to a computer and are comfortable inputting their Social Security Number over the Internet. We view this work as an important methodological first step, and encourage further studies to cross validate the results in other populations.</p><p>The willingness-to-accept estimates can be multiplied by the number of boxes to estimate the annually recurring impact of these restrictions on consumer welfare if all states were to implement behind-the-counter or prescription requirements. While no national estimates of boxes of pseudoephedrine sales exist, annual sales of pseudoephedrine by weight were estimated at 203,734 kg for 2010 [<xref rid="pone.0126790.ref031" ref-type="bibr">31</xref>]. A large box of pseudoephedrine contains 96 pills, and each pill contains 30 mg of pseudoephedrine. If all pseudoephedrine went into boxes with this configuration, there were 70,740,972 boxes sold nationwide in 2010. The DEA estimates 19.5% of retail, over-the-counter sales of pseudo were diverted to legitimate use [<xref rid="pone.0126790.ref032" ref-type="bibr">32</xref>]. Multiplying the estimated 56,946,482 boxes sold for legitimate use by the impacts on consumer welfare from our model, we estimate approximately $550 million in lost consumer welfare for behind-the-counter restrictions and $810 million in lost consumer welfare if prescriptions were required nationwide for pseudo purchases. These costs must be balanced against potential benefits from the restrictions that lower methamphetamine production and use.</p><p>Restricting access to medicines as a means of reducing the social costs of non-medical use can imply large inconvenience costs for legitimate consumers. Here we estimate these costs, although comparisons with the potential benefits of these restrictions need to be conducted on a case-by-case basis for each drug. This work has potential implications for estimating the benefits of making other medications available over-the-counter.</p></sec><sec sec-type="supplementary-material" id="sec012"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0126790.s001"><label>S1 Pseudo Orientation</label><caption><title>Orientation for survey participants to decongestant medications.</title><p>(PDF)</p></caption><media xlink:href="pone.0126790.s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0126790.s002"><label>S1 Dataset</label><caption><title>Dataset with survey responses to reproduce conditional logit model.</title><p>(DTA)</p></caption><media xlink:href="pone.0126790.s002.dta"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We have benefitted from discussions with Jim Alm, Jay Shimshack, and participants from the Tulane University Murphy Institute Health Policy Working Group.</p></ack><ref-list><title>References</title><ref id="pone.0126790.ref001"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Iritani</surname><given-names>BJ</given-names></name>, <name><surname>Hallfors</surname><given-names>DD</given-names></name>, <name><surname>Bauer</surname><given-names>DJ</given-names></name>. <article-title>Crystal methamphetamine use among young adults in the usa</article-title>. <source>Addiction</source>
<year>2007</year>;<volume>102</volume>: <fpage>1102</fpage>&#x02013;<lpage>13</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1360-0443.2007.01847.x">10.1111/j.1360-0443.2007.01847.x</ext-link></comment>
<pub-id pub-id-type="pmid">17567398</pub-id></mixed-citation></ref><ref id="pone.0126790.ref002"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Kaye</surname><given-names>S</given-names></name>, <name><surname>McKetin</surname><given-names>R</given-names></name>, <name><surname>Duflou</surname><given-names>J</given-names></name>, <name><surname>Darke</surname><given-names>S</given-names></name>. <article-title>Methamphetamine and cardiovascular pathology: A review of the evidence</article-title>. <source>Addiction</source>
<year>2007</year>;<volume>102</volume>: <fpage>1204</fpage>&#x02013;<lpage>11</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1360-0443.2007.01874.x">10.1111/j.1360-0443.2007.01874.x</ext-link></comment>
<pub-id pub-id-type="pmid">17565561</pub-id></mixed-citation></ref><ref id="pone.0126790.ref003"><label>3</label><mixed-citation publication-type="journal">
<name><surname>McKetin</surname><given-names>R</given-names></name>, <name><surname>Lubman</surname><given-names>DI</given-names></name>, <name><surname>Najman</surname><given-names>JM</given-names></name>, <name><surname>Dawe</surname><given-names>S</given-names></name>, <name><surname>Butterworth</surname><given-names>P</given-names></name>, <name><surname>Baker</surname><given-names>AL</given-names></name>. <article-title>Does methamphetamine use increase violent behaviour? Evidence from a prospective longitudinal study</article-title>. <source>Addiction</source>
<year>2014</year>;<volume>109</volume>: <fpage>798</fpage>&#x02013;<lpage>806</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/add.12474">10.1111/add.12474</ext-link></comment>
<pub-id pub-id-type="pmid">24400972</pub-id></mixed-citation></ref><ref id="pone.0126790.ref004"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Shoptaw</surname><given-names>S</given-names></name>, <name><surname>Reback</surname><given-names>CJ</given-names></name>. <article-title>Methamphetamine use and infectious disease-related behaviors in men who have sex with men: Implications for interventions</article-title>. <source>Addiction</source>
<year>2007</year>;<volume>102</volume>: <fpage>130</fpage>&#x02013;<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1360-0443.2006.01775.x">10.1111/j.1360-0443.2006.01775.x</ext-link></comment>
<pub-id pub-id-type="pmid">17493062</pub-id></mixed-citation></ref><ref id="pone.0126790.ref005"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Barr</surname><given-names>AM</given-names></name>, <name><surname>Panenka</surname><given-names>WJ</given-names></name>, <name><surname>MacEwan</surname><given-names>GW</given-names></name>, <name><surname>Thornton</surname><given-names>AE</given-names></name>, <name><surname>Lang</surname><given-names>DJ</given-names></name>, <name><surname>Honer</surname><given-names>WG</given-names></name>, <etal>et al</etal>
<article-title>The need for speed: An update on methamphetamine addiction</article-title>. <source>Journal of Psychiatry and Neuroscience</source>
<year>2006</year>;<volume>31</volume>: <fpage>301</fpage>&#x02013;<lpage>13</lpage>.
<pub-id pub-id-type="pmid">16951733</pub-id></mixed-citation></ref><ref id="pone.0126790.ref006"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Talbert</surname><given-names>J</given-names></name>, <name><surname>Blumenschein</surname><given-names>K</given-names></name>, <name><surname>Burke</surname><given-names>A</given-names></name>, <name><surname>Stromberg</surname><given-names>A</given-names></name>, <name><surname>Freeman</surname><given-names>P</given-names></name>. <article-title>Pseudoephedrine sales and seizures of clandestine methamphetamine laboratories in Kentucky</article-title>. <source>Journal of the American Medical Association</source>
<year>2012</year>;<volume>308</volume>: <fpage>1524</fpage>&#x02013;<lpage>26</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jama.2012.12992">10.1001/jama.2012.12992</ext-link></comment>
<pub-id pub-id-type="pmid">23073945</pub-id></mixed-citation></ref><ref id="pone.0126790.ref007"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Hershey</surname><given-names>MR</given-names></name>. <article-title>What we know about voter-ID laws, registration, and turnout laws, registration, and turnout</article-title>. <source>PS: Political Science and Politics</source>
<year>2009</year>;<volume>42</volume>: <fpage>87</fpage>&#x02013;<lpage>91</lpage>.</mixed-citation></ref><ref id="pone.0126790.ref008"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Ryan</surname><given-names>M</given-names></name>, <name><surname>Yule</surname><given-names>B</given-names></name>. <article-title>Switching drugs from prescription-only to over-the-counter availability: Economic benefits in the United Kingdom</article-title>. <source>Health Policy</source>
<year>1990</year>;<volume>16</volume>: <fpage>233</fpage>&#x02013;<lpage>39</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/0168-8510(90)90424-C">10.1016/0168-8510(90)90424-C</ext-link></comment>
<pub-id pub-id-type="pmid">10113545</pub-id></mixed-citation></ref><ref id="pone.0126790.ref009"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Wood</surname><given-names>AJ</given-names></name>, <name><surname>Brass</surname><given-names>EP</given-names></name>. <article-title>Changing the status of drugs from prescription to over-the-counter availability</article-title>. <source>New England Journal of Medicine</source>
<year>2001</year>;<volume>345</volume>: <fpage>810</fpage>&#x02013;<lpage>16</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMra011080">10.1056/NEJMra011080</ext-link></comment>
<pub-id pub-id-type="pmid">11556302</pub-id></mixed-citation></ref><ref id="pone.0126790.ref010"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Prasad</surname><given-names>M</given-names></name>, <name><surname>Shih</surname><given-names>Y</given-names></name>, <name><surname>Luce</surname><given-names>B</given-names></name>. <article-title>Clinical, public health, and economic issues associated with switching second-generation antihistamines from prescription to over-the-counter</article-title>. <source>Value in Health</source>
<year>2002</year>;<volume>5</volume>: <fpage>193</fpage>&#x02013;<lpage>93</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1098-3015(10)60991-6">10.1016/S1098-3015(10)60991-6</ext-link></comment>
</mixed-citation></ref><ref id="pone.0126790.ref011"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Reynolds</surname><given-names>T</given-names></name>. <article-title>Switching from prescription to over the counter</article-title>. <source>Annals of Internal Medicine</source>
<year>2002</year>;<volume>136</volume>: <fpage>177</fpage>&#x02013;<lpage>80</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.7326/0003-4819-136-2-200201150-00026">10.7326/0003-4819-136-2-200201150-00026</ext-link></comment>
<pub-id pub-id-type="pmid">11790082</pub-id></mixed-citation></ref><ref id="pone.0126790.ref012"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Cohen</surname><given-names>JP</given-names></name>. <article-title>Switching prescription drugs to over the counter</article-title>. <source>BMJ</source>
<year>2005</year>;<volume>330</volume>: <fpage>39</fpage>&#x02013;<lpage>41</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/bmj.330.7481.39">10.1136/bmj.330.7481.39</ext-link></comment>
<pub-id pub-id-type="pmid">15626806</pub-id></mixed-citation></ref><ref id="pone.0126790.ref013"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Hatton</surname><given-names>RC</given-names></name>, <name><surname>Winterstein</surname><given-names>AG</given-names></name>, <name><surname>McKelvey</surname><given-names>RP</given-names></name>, <name><surname>Shuster</surname><given-names>J</given-names></name>, <name><surname>Hendeles</surname><given-names>L</given-names></name>. <article-title>Efficacy and safety of oral phenylephrine: Systematic review and meta-analysis</article-title>. <source>Annals of Pharmacotherapy</source>
<year>2007</year>;<volume>41</volume>: <fpage>381</fpage>&#x02013;<lpage>90</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1345/aph.1H679">10.1345/aph.1H679</ext-link></comment>
<pub-id pub-id-type="pmid">17264159</pub-id></mixed-citation></ref><ref id="pone.0126790.ref014"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Eccles</surname><given-names>R</given-names></name>. <article-title>Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse</article-title>. <source>British Journal of Clinical Pharmacology</source>
<year>2007</year>;<volume>63</volume>: <fpage>10</fpage>&#x02013;<lpage>14</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1365-2125.2006.02833.x">10.1111/j.1365-2125.2006.02833.x</ext-link></comment>
<pub-id pub-id-type="pmid">17116124</pub-id></mixed-citation></ref><ref id="pone.0126790.ref015"><label>15</label><mixed-citation publication-type="journal">
<name><surname>DeShazo</surname><given-names>J</given-names></name>, <name><surname>Fermo</surname><given-names>G</given-names></name>. <article-title>Designing choice sets for stated preference methods: The effects of complexity on choice consistency</article-title>. <source>Journal of Environmental Economics and Management</source>
<year>2002</year>;<volume>44</volume>: <fpage>123</fpage>&#x02013;<lpage>43</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1006/jeem.2001.1199">10.1006/jeem.2001.1199</ext-link></comment>
</mixed-citation></ref><ref id="pone.0126790.ref016"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Louviere</surname><given-names>JJ</given-names></name>, <name><surname>Islam</surname><given-names>T</given-names></name>, <name><surname>Wasi</surname><given-names>N</given-names></name>, <name><surname>Street</surname><given-names>D</given-names></name>, <name><surname>Burgess</surname><given-names>L</given-names></name>. <article-title>Designing discrete choice experiments: Do optimal designs come at a price?</article-title>
<source>Journal of Consumer Research</source>
<year>2008</year>;<volume>35</volume>: <fpage>360</fpage>&#x02013;<lpage>75</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/586913">10.1086/586913</ext-link></comment>
</mixed-citation></ref><ref id="pone.0126790.ref017"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Wiley</surname><given-names>JB</given-names></name>. <article-title>Selecting pareto optimal subsets from multiattribute alternatives</article-title>. <source>Advances in Consumer Research</source>
<year>1978</year>;<volume>5</volume>: <fpage>171</fpage>&#x02013;<lpage>74</lpage>.</mixed-citation></ref><ref id="pone.0126790.ref018"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Krieger</surname><given-names>AM</given-names></name>, <name><surname>Green</surname><given-names>PE</given-names></name>. <article-title>Designing pareto optimal stimuli for multiattribute choice experiments</article-title>. <source>Marketing Letters</source>
<year>1991</year>;<volume>2</volume>: <fpage>337</fpage>&#x02013;<lpage>48</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/BF00664220">10.1007/BF00664220</ext-link></comment>
</mixed-citation></ref><ref id="pone.0126790.ref019"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Hanley</surname><given-names>N</given-names></name>, <name><surname>MacMillan</surname><given-names>D</given-names></name>, <name><surname>Wright</surname><given-names>RE</given-names></name>, <name><surname>Bullock</surname><given-names>C</given-names></name>, <name><surname>Simpson</surname><given-names>I</given-names></name>, <etal>et al</etal>
<article-title>Contingent valuation versus choice experiments: Estimating the benefits of environmentally sensitive areas in Scotland</article-title>. <source>Journal of Agricultural Economics</source>
<year>1998</year>;<volume>49</volume>: <fpage>1</fpage>&#x02013;<lpage>15</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1477-9552.1998.tb01248.x">10.1111/j.1477-9552.1998.tb01248.x</ext-link></comment>
</mixed-citation></ref><ref id="pone.0126790.ref020"><label>20</label><mixed-citation publication-type="journal">
<name><surname>de Bekker-Grob</surname><given-names>EW</given-names></name>, <name><surname>Ryan</surname><given-names>M</given-names></name>, <name><surname>Gerard</surname><given-names>K</given-names></name>. <article-title>Discrete choice experiments in health economics: A review of the literature</article-title>. <source>Health Economics</source>
<year>2012</year>;<volume>21</volume>: <fpage>145</fpage>&#x02013;<lpage>72</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/hec.1697">10.1002/hec.1697</ext-link></comment>
<pub-id pub-id-type="pmid">22223558</pub-id></mixed-citation></ref><ref id="pone.0126790.ref021"><label>21</label><mixed-citation publication-type="book">
<name><surname>Hensher</surname><given-names>DA</given-names></name>, <name><surname>Rose</surname><given-names>JM</given-names></name>, <name><surname>Greene</surname><given-names>WH</given-names></name>. <source>Applied Choice Analysis: A Primer</source>. <publisher-name>Cambridge University Press</publisher-name>; <year>2005</year>
<comment>URL <ext-link ext-link-type="uri" xlink:href="http://www.amazon.com/Applied-Choice-Analysis-A-Primer/dp/0521605776">http://www.amazon.com/Applied-Choice-Analysis-A-Primer/dp/0521605776</ext-link></comment>
</mixed-citation></ref><ref id="pone.0126790.ref022"><label>22</label><mixed-citation publication-type="book">
<name><surname>Louviere</surname><given-names>JJ</given-names></name>, <name><surname>Hensher</surname><given-names>DA</given-names></name>, <name><surname>Swait</surname><given-names>JD</given-names></name>. <source>Stated Choice Methods: Analysis and Applications</source>. <publisher-name>Cambridge University Press</publisher-name>; <year>2000</year>
<comment>URL <ext-link ext-link-type="uri" xlink:href="http://www.amazon.com/Stated-Choice-Methods-Analysis-Applications/dp/0521788307">http://www.amazon.com/Stated-Choice-Methods-Analysis-Applications/dp/0521788307</ext-link></comment>
</mixed-citation></ref><ref id="pone.0126790.ref023"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Paolacci</surname><given-names>G</given-names></name>, <name><surname>Chandler</surname><given-names>J</given-names></name>, <name><surname>Ipeirotis</surname><given-names>PG</given-names></name>. <article-title>Running experiments on Amazon Mechanical Turk</article-title>. <source>Judgment and Decision Making</source>
<year>2010</year>;<volume>5</volume>: <fpage>411</fpage>&#x02013;<lpage>19</lpage>.</mixed-citation></ref><ref id="pone.0126790.ref024"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Horton</surname><given-names>JJ</given-names></name>, <name><surname>Rand</surname><given-names>DG</given-names></name>, <name><surname>Zeckhauser</surname><given-names>RJ</given-names></name>. <article-title>The online laboratory: Conducting experiments in a real labor market</article-title>. <source>Experimental Economics</source>
<year>2011</year>;<volume>14</volume>: <fpage>399</fpage>&#x02013;<lpage>425</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10683-011-9273-9">10.1007/s10683-011-9273-9</ext-link></comment>
</mixed-citation></ref><ref id="pone.0126790.ref025"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Buhrmester</surname><given-names>M</given-names></name>, <name><surname>Kwang</surname><given-names>T</given-names></name>, <name><surname>Gosling</surname><given-names>SD</given-names></name>. <article-title>Amazon&#x02019;s Mechanical Turk: A new source of inexpensive, yet high-quality, data?</article-title>
<source>Perspectives on Psychological Science</source>
<year>2011</year>;<volume>6</volume>: <fpage>3</fpage>&#x02013;<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1177/1745691610393980">10.1177/1745691610393980</ext-link></comment>
<pub-id pub-id-type="pmid">26162106</pub-id></mixed-citation></ref><ref id="pone.0126790.ref026"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Simons</surname><given-names>DJ</given-names></name>, <name><surname>Chabris</surname><given-names>CF</given-names></name>. <article-title>Common (mis)beliefs about memory: A replication and comparison of telephone and Mechanical Turk survey methods</article-title>. <source>PLoS ONE</source>
<year>2012</year>;<volume>7</volume>: <fpage>e51876</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0051876">10.1371/journal.pone.0051876</ext-link></comment>
<pub-id pub-id-type="pmid">23272183</pub-id></mixed-citation></ref><ref id="pone.0126790.ref027"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Oehlert</surname><given-names>GW</given-names></name>. <article-title>A note on the delta method</article-title>. <source>American Statistician</source>
<year>1992</year>;<volume>46</volume>: <fpage>27</fpage>&#x02013;<lpage>29</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1080/00031305.1992.10475842">10.1080/00031305.1992.10475842</ext-link></comment>
</mixed-citation></ref><ref id="pone.0126790.ref028"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Luchini</surname><given-names>S</given-names></name>, <name><surname>Watson</surname><given-names>V</given-names></name>. <article-title>Are choice experiments reliable? Evidence from the lab</article-title>. <source>Economics Letters</source>
<year>2014</year>;<volume>124</volume>: <fpage>9</fpage>&#x02013;<lpage>13</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.econlet.2014.04.005">10.1016/j.econlet.2014.04.005</ext-link></comment>
</mixed-citation></ref><ref id="pone.0126790.ref029"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Berinsky</surname><given-names>AJ</given-names></name>, <name><surname>Huber</surname><given-names>GA</given-names></name>, <name><surname>Lenz</surname><given-names>GS</given-names></name>. <article-title>Evaluating online labor markets for experimental research: Amazon.com&#x02019;s Mechanical Turk</article-title>. <source>Political Analysis</source>
<year>2012</year>;<volume>20</volume>: <fpage>351</fpage>&#x02013;<lpage>68</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/pan/mpr057">10.1093/pan/mpr057</ext-link></comment>
</mixed-citation></ref><ref id="pone.0126790.ref030"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Krupnikov</surname><given-names>Y</given-names></name>, <name><surname>Levine</surname><given-names>AS</given-names></name>. <article-title>Cross-sample comparisons and external validity</article-title>. <source>Journal of Experimental Political Science</source>
<year>2014</year>;<volume>1</volume>: <fpage>59</fpage>&#x02013;<lpage>80</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1017/xps.2014.7">10.1017/xps.2014.7</ext-link></comment>
</mixed-citation></ref><ref id="pone.0126790.ref031"><label>31</label><mixed-citation publication-type="journal">
<collab>[US DEA] United States Drug Enforcement Administration</collab>. <article-title>Established assessment of annual needs for the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine for 2011</article-title>. <source>Federal Register</source>
<year>2010</year>;<volume>75</volume>: <fpage>79407</fpage>&#x02013;<lpage>12</lpage>.</mixed-citation></ref><ref id="pone.0126790.ref032"><label>32</label><mixed-citation publication-type="other">[US DEA] United States Drug Enforcement Administration. 2005 ephedrine / pseudoephedrine legitimate medical use methodology and final report. URL <ext-link ext-link-type="uri" xlink:href="http://www.deadiversion.usdoj.gov/meth/dea_ims_study_070307.pdf">http://www.deadiversion.usdoj.gov/meth/dea_ims_study_070307.pdf</ext-link>. Report prepared by IMS Government Solutions; 2007.</mixed-citation></ref></ref-list></back></article>